CD40 and head and neck squamous cell carcinoma: Other novel approaches have been used to effectively target TAMs (NCT03329950, NCT03795610), e.g., using the CD40 agonist or PI3Kγ inhibitor in combination with ICIs (nivolumab and pembrolizumab) to increase the efficacy of immunological therapies in HNSCC patients [48].